These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 10327033)
1. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Groener MG; van Ineveld BM; Byttebier G; van Hout BA; Rutten FF Anticancer Drugs; 1999 Mar; 10(3):283-8. PubMed ID: 10327033 [TBL] [Abstract][Full Text] [Related]
2. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Sculpher M; Palmer MK; Heyes A Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491 [TBL] [Abstract][Full Text] [Related]
3. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Cunningham D Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851 [TBL] [Abstract][Full Text] [Related]
4. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562 [TBL] [Abstract][Full Text] [Related]
5. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146 [TBL] [Abstract][Full Text] [Related]
6. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Ross P; Heron J; Cunningham D Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037 [TBL] [Abstract][Full Text] [Related]
7. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Gunasekara NS; Faulds D Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547 [TBL] [Abstract][Full Text] [Related]
8. [Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review]. Selke B; Lebrun T; Comte S Bull Cancer; 2003 Feb; 90(2):143-9. PubMed ID: 12660133 [TBL] [Abstract][Full Text] [Related]
9. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Kerr DJ Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632 [TBL] [Abstract][Full Text] [Related]
11. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416 [TBL] [Abstract][Full Text] [Related]
12. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer. Zalcberg J Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633 [TBL] [Abstract][Full Text] [Related]
13. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887 [TBL] [Abstract][Full Text] [Related]
14. Raltitrexed-based chemotherapy for advanced colorectal cancer. Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M; Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670 [TBL] [Abstract][Full Text] [Related]
16. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer. Aristides M; Chen J; Schulz M; Williamson E; Clarke S; Grant K Pharmacoeconomics; 2002; 20(11):775-84. PubMed ID: 12201796 [TBL] [Abstract][Full Text] [Related]
17. The costs of managing advanced colorectal cancer: a broad perspective. Kerr DJ; O'Connor KM Anticancer Drugs; 1997 Aug; 8 Suppl 2():S23-6. PubMed ID: 9376634 [TBL] [Abstract][Full Text] [Related]
18. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial]. Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535 [TBL] [Abstract][Full Text] [Related]
19. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748 [No Abstract] [Full Text] [Related]